Trial Profile

Phase 1/2 clinical trial for LP-184 in Glioblastoma multiform

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irofulven (Primary) ; Spironolactone
Indications Glioblastoma
Focus Adverse reactions
Sponsors Starlight Therapeutics

Most Recent Events

07 Nov 2024 According to a Lantern Pharma media release, trial targeted to begin in early 2025
15 Oct 2024 According to a Lantern Pharma media release, trial to begin in late 2024 or early 2025.
03 Oct 2023 According to a Lantern Pharma media release, Lantern anticipates the Phase 1A portion of the trial to be completed in the first half of 2024 and a Phase 2 trial in GBM and other CNS cancers to begin in the second half of 2024. The anticipated Phase 2 trial will be conducted by Starlight Therapeutics, a wholly owned subsidiary of Lantern focused entirely on CNS and brain cancer indications.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com